Second line therapy in multiple myeloma: A SEER Medicare analysis

Introduction: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals since 2012. We characterized population-level trends in RRMM therapy selection, survival and cost outcomes associated with RRMM treatment over time.Materials and Methods: Our cohort included adults diagnosed with multiple myeloma (MM) in the SEER-Medicare database from 2007 – 2017 who received at least one antimyeloma agent. MM-directed therapies and lines of therapy were identified.

Source: Clinical Lymphoma, Myeloma and Leukemia - April 18, 2024 Category: Hematology Authors: Matthew R LeBlanc, Xi Zhou, Christopher D Baggett, Sascha Tuchman, Christopher E Jensen, Samuel Rubinstein Tags: Original Study Source Type: research